Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-11 |
2024-09 |
-0.4 |
N/A |
N/A |
N/A |
2024-08-06 |
2024-06 |
-0.44 |
-0.31 |
0.13 |
29.55% |
2024-05-14 |
2024-03 |
-0.57 |
-0.34 |
0.23 |
40.35% |
2024-05-14 |
2024-03 |
-0.57 |
N/A |
N/A |
N/A |
2024-04-15 |
2023-12 |
0 |
-0.53 |
N/A |
N/A |
2024-04-15 |
2023-12 |
0 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-08-08 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-06-25 |
Wedbush |
Downgrade |
Outperform |
Neutral |
2023-05-30 |
Roth MKM |
Upgrade |
|
Buy |
2023-05-25 |
Citigroup |
Upgrade |
Buy |
Buy |
2023-05-09 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-04-24 |
Wedbush |
Upgrade |
|
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2023-03-30 |
DANANBERG JAMIE |
Officer |
62.82K |
Sale |
2024-08-01 |
GHOSH ANIRVAN |
Chief Executive Officer |
76.33K |
Sale |
2024-08-01 |
NGUYEN ALEXANDER HIEU |
Officer |
24.87K |
Sale |
2024-08-01 |
SULLIVAN LYNNE MARIE |
Chief Financial Officer |
56.06K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Arch Venture Management, Llc |
1.00M |
2.56M |
6.88% |
2023-06-29 |
Vanguard Group Inc |
562.96K |
1.44M |
3.86% |
2023-06-29 |
UBS OConnor LLC |
179.08K |
456.65K |
1.23% |
2023-06-29 |
Geode Capital Management, LLC |
126.11K |
321.58K |
0.86% |
2023-06-29 |
Mayo Clinic |
124.08K |
316.41K |
0.85% |
2023-06-29 |
Blackrock Inc. |
114.85K |
292.86K |
0.79% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
357.57K |
911.80K |
2.45% |
2023-06-29 |
Vanguard Extended Market Index Fund |
194.79K |
496.70K |
1.33% |
2023-05-30 |
Fidelity Extended Market Index Fund |
64.11K |
192.96K |
0.44% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Market Fund |
50.00K |
127.50K |
0.34% |
2023-08-30 |
iShares Micro Cap ETF |
29.93K |
79.32K |
0.21% |
2023-05-30 |
Fidelity Total Market Index Fund |
27.73K |
83.46K |
0.19% |
Split |
Date |
1 : 10 |
2022-10-20 |